title: Antibody Persistence 1-5 Years Following Vaccination With MenAfriVac in African Children Vaccinated at 12-23 Months of Age.
abstract: BACKGROUND
  Following mass vaccination campaigns in the African meningitis belt with group A meningococcal conjugate vaccine, MenAfriVac (PsA-TT), disease due to group A meningococci has nearly disappeared. Antibody persistence in healthy African toddlers was investigated.
  
  
  METHODS
  African children vaccinated at 12-23 months of age with PsA-TT were followed for evaluation of antibody persistence up to 5 years after primary vaccination. Antibody persistence was evaluated by measuring group A serum bactericidal antibody (SBA) with rabbit complement and by a group A-specific IgG enzyme-linked immunosorbent assay (ELISA).
  
  
  RESULTS
  Group A antibodies measured by SBA and ELISA were shown to decline in the year following vaccination and plateaued at levels significantly above baseline for up to 5 years following primary vaccination.
  
  
  CONCLUSIONS
  A single dose of PsA-TT induces long-term sustained levels of group A meningococcal antibodies for up to 5 years after vaccination.
  
  
  BACKGROUND
  ISRTCN78147026.
authors.affiliation: Department of Pediatrics, Center for Vaccine Development, University of Maryland School of Medicine, Baltimore.
authors.forename: Milagritos D
authors.initials: MD
authors.lastname: Tapia
authors.affiliation: Vaccine Evaluation Unit, Public Health England, Manchester Royal Infirmary, United Kingdom.
authors.forename: Helen
authors.initials: H
authors.lastname: Findlow
authors.affiliation: Vaccines and Immunity Theme, Medical Research Council Unit, Basse, The Gambia.
authors.forename: Olubukola T
authors.initials: OT
authors.lastname: Idoko
authors.affiliation: Meningitis Vaccine Project, PATH, Ferney-Voltaire, France Meningitis Vaccine Project, Department of Immunization, Vaccines and Biologicals, World Health Organization, Geneva, Switzerland.
authors.forename: Marie-Pierre
authors.initials: MP
authors.lastname: Preziosi
authors.affiliation: Serum Institute of India, Ltd, Pune.
authors.forename: Prasad S
authors.initials: PS
authors.lastname: Kulkarni
authors.affiliation: Meningitis Vaccine Project, PATH, Ferney-Voltaire, France.
authors.forename: Godwin C
authors.initials: GC
authors.lastname: Enwere
authors.affiliation: Centers for Disease Control and Prevention, Atlanta, Georgia.
authors.forename: Cheryl
authors.initials: C
authors.lastname: Elie
authors.affiliation: DiagnoSearch Life Sciences, Mumbai, India.
authors.forename: Varsha
authors.initials: V
authors.lastname: Parulekar
authors.affiliation: Centre pour le Développement des Vaccins, Ministère de la Santé, Bamako, Mali.
authors.forename: Samba O
authors.initials: SO
authors.lastname: Sow
authors.affiliation: Centre pour le Développement des Vaccins, Ministère de la Santé, Bamako, Mali.
authors.forename: Fadima Cheick
authors.initials: FC
authors.lastname: Haidara
authors.affiliation: Centre pour le Développement des Vaccins, Ministère de la Santé, Bamako, Mali.
authors.forename: Fatoumata
authors.initials: F
authors.lastname: Diallo
authors.affiliation: Centre pour le Développement des Vaccins, Ministère de la Santé, Bamako, Mali.
authors.forename: Moussa
authors.initials: M
authors.lastname: Doumbia
authors.affiliation: Vaccines and Immunity Theme, Medical Research Council Unit, Basse, The Gambia.
authors.forename: Adebayo K
authors.initials: AK
authors.lastname: Akinsola
authors.affiliation: GlaxoSmithKline Vaccines, Wavre, Belgium.
authors.forename: Richard A
authors.initials: RA
authors.lastname: Adegbola
authors.affiliation: Vaccines and Immunity Theme, Medical Research Council Unit, Basse, The Gambia.
authors.forename: Beate
authors.initials: B
authors.lastname: Kampmann
authors.affiliation: Meningitis Vaccine Project, PATH, Ferney-Voltaire, France.
authors.forename: Julie
authors.initials: J
authors.lastname: Chaumont
authors.affiliation: Meningitis Vaccine Project, PATH, Ferney-Voltaire, France.
authors.forename: Lionel
authors.initials: L
authors.lastname: Martellet
authors.affiliation: Meningitis Vaccine Project, PATH, Ferney-Voltaire, France.
authors.forename: Elisa
authors.initials: E
authors.lastname: Marchetti
authors.affiliation: Meningitis Vaccine Project, PATH, Ferney-Voltaire, France.
authors.forename: Simonetta
authors.initials: S
authors.lastname: Viviani
authors.affiliation: Meningitis Vaccine Project, PATH, Seattle, WA.
authors.forename: Yuxiao
authors.initials: Y
authors.lastname: Tang
authors.affiliation: Centers for Disease Control and Prevention, Atlanta, Georgia.
authors.forename: Brian D
authors.initials: BD
authors.lastname: Plikaytis
authors.affiliation: Serum Institute of India, Ltd, Pune.
authors.forename: F Marc
authors.initials: FM
authors.lastname: LaForce
authors.affiliation: Centers for Disease Control and Prevention, Atlanta, Georgia.
authors.forename: George
authors.initials: G
authors.lastname: Carlone
authors.affiliation: Vaccine Evaluation Unit, Public Health England, Manchester Royal Infirmary, United Kingdom.
authors.forename: Ray
authors.initials: R
authors.lastname: Borrow
mesh_terms: D000349:Africa; D000818:Animals; D000907:Antibodies, Bacterial / Q000097:blood*; D001770:Blood Bactericidal Activity; D003165:Complement System Proteins; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007074:Immunoglobulin G / Q000097:blood; D007223:Infant; D008297:Male; D022401:Meningococcal Vaccines / Q000008:administration & dosage* / Q000276:immunology*; D011817:Rabbits; D013997:Time Factors
chemical_list: D000907:Antibodies, Bacterial; D007074:Immunoglobulin G; C573970:MenAfriVac; D022401:Meningococcal Vaccines; D003165:Complement System Proteins
keywords: African meningitis belt; MenAfriVac; antibody persistence; group A meningococcal conjugate vaccine